Research programme: non-catalytic site HIV integrase inhibitors - Gilead

Drug Profile

Research programme: non-catalytic site HIV integrase inhibitors - Gilead

Alternative Names: GS 9695; GS 9822; Non-catalytic site HIV integrase inhibitors - Boehringer Ingelheim

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Gilead Sciences
  • Class Anti-infectives; Antivirals
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 13 Feb 2017 Adverse events, pharmacodynamic data and pharmacokinetic data from preclinical study in HIV-infections presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
  • 13 Feb 2017 Preclinical development in HIV-infections is ongoing in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top